Brostallicin: Interim Phase II data

Interim data from 47 evaluable patients with metastatic TNBC in an open-label, U.S. Phase II trial showed that brostallicin plus cisplatin led to a 3-month PFS rate of 51% and a 6-month PFS rate of 26...